Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Mithra Pharmaceuticals SA MITRA.BR
$2.43
-$0.03 (-1.22%)
На 18:01, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
149283631.00000000
-
week52high
9.75
-
week52low
2.28
-
Revenue
66997000
-
P/E TTM
-2
-
Beta
0.70572500
-
EPS
-0.97000000
-
Last Dividend
0.00000000
-
Next Earnings Date
07 мар 2023 г. в 10:59
Описание компании
Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial, which is a combined oral contraceptive; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a solution for treating menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it offers NEXTSTELLIS, an oral contraceptive pill. In addition, the company provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. Mithra Pharmaceuticals SA was founded in 1999 and is headquartered in Liège, Belgium.
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Свежие комментарии
Свежие комментарии